Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
5.05
-0.08 (-1.56%)
At close: Feb 20, 2026, 4:00 PM EST
5.21
+0.16 (3.17%)
After-hours: Feb 20, 2026, 6:18 PM EST
Bolt Biotherapeutics Employees
Bolt Biotherapeutics had 40 employees as of September 30, 2025. The number of employees decreased by 12 or -23.08% compared to the same quarter last year.
Employees
40
Change
-12
Growth
-23.08%
Revenue / Employee
$129,875
Profits / Employee
-$1,067,025
Market Cap
9.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 40 | -12 | -23.08% |
| Dec 31, 2024 | 52 | -48 | -48.00% |
| Dec 31, 2023 | 100 | 6 | 6.38% |
| Dec 31, 2022 | 94 | 3 | 3.30% |
| Dec 31, 2021 | 91 | 26 | 40.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 57 |
| Quince Therapeutics | 36 |
| Imunon | 25 |
| NuCana | 22 |
| BioVie | 13 |
| Akari Therapeutics, | 9 |
| TransCode Therapeutics | 7 |
| Ernexa Therapeutics | 6 |
BOLT News
- 3 months ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 6 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 11 months ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire